Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Endoscopic ultrasound-guided ablation
7 evidence topics · 7 sources
Radiofrequency ablation for small localized insulinoma: ENETS guidance
Nonsurgical ablation for localized insulinoma: clinical review
“Nonsurgical therapy can be considered in patients who either have comorbidities precluding resection or do not want to undergo resection after being appropriately counseled about therapeutic options. In selected cases, curative EUS-guided radiofrequency ablation of a localized insulinoma can be feasible and safe, although long-term data are pending (19, 54, 103, 109–112).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison
“Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prospective multicenter radiofrequency ablation including 30 insulinomas
“During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight AEs occurred peri-procedurally, including five cases of mild acute pancreatitis all managed conservatively without prolongation of hospital stay or occurrence of any sequelae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethanol and radiofrequency ablation of insulinoma: systematic review of published cases
“In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical success rate for EUS-guided ablation techniques was 98.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethanol ablation versus surgery for insulinoma: single-center comparison
“Of these, 9 patients were treated with EUS-guided ethanol injection and 24 underwent pancreatic surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest glucose values were similar between groups before (ethanol: 2.09±0.17 mmol/l vs. surgery: 1.81±0.08, p=0.158) and after (4.95±0.74 vs. 5.41±0.28, p=0.581) the respective treatments. Complications occurred more frequently in the surgery group (11 % vs. 54 %, p=0.026). One patient after prior partial pancreatectomy died postoperatively. The hospitalization time was significantly shorter in the ethanol group (4.78±0.78 days vs. 19.88±4.07, p<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote